Currently working as a professor of Oncology at the Roswell Park Cancer Institute, Mikhail Blagosklonny is a scientist who focuses on Aging and Cancer. He acquired an MD in Internal Medicine from the First Pavlov State Medical University of St. Petersburg and advanced to get a Ph. D. in Experimental Medicine and Cardiology. In 2002 when at the New York Medical College, he was made the associate professor of Medicine, but joined Ordway Research Institute working as the senior scientist before finally moving to Roswell Park Cancer Institute in 2009. Then, he held the position of Professor of Oncology. Visit classroomvoices.org to read more about Mikhail.
Professor Mikhail Blagosklonny’s research is mainly interested in cellular and molecular biology as well as clinical investigation. In clinical investigation, his focus is on oncogenes and tumor suppressions, anticancer therapeutics, cell cycle, apoptosis, signal transduction, mitosis and signal transduction. He has tried to work in exploiting cancer cell cycling and their resistance as a method of protecting normal cells. His interest in aging and age related diseases has led to discovery of drugs such as Rapamycin. From this, he has written a theory of aging and many other anti-cancer practices. Mikhail is the publisher of 300 research articles and book chapters. Some of the pieces he has edited include Aging, Cell Cycle, Oncosciencse, Oncotarget, Autophagy, Cell and Death Differentiation, PLOS one and The American Journal of Pathology.
As a result of his research and theories, Dr. Mikhail Blagosklonny was recognized by the longevity research as one of the most passionate advocates of Rapamycin. This was after he brilliantly came up with the theory on TOR, signaling potential use in aging and cancer. His hypothesis suggests the use of Rapamycin which had been previously used for cancer treatment, as a treatment that has the effect of extending life.
On April 15, 2009, Mikhail Blagosklonny was appointed as a member of the Roswell Park Cancer Institute. The Senior Vice President of the Basic Science department, Andrei V Gudkov, described him as a pre-eminent researcher with unique concepts about cancer. He viewed his addition to the team as a plus as they had similar ideas. Read more on Hardware Gurus.